Bioreactors for cell therapies: Current status and future advances

详细信息    查看全文

• 作者：Shannon Eaker¹ ; ^* ; ^{shannon.eaker@ge.com} ; Eytan Abraham² ; ^* ; Julie Allickson³ ; ^* ; Thomas A. Brieva⁴ ; ^* ; Dolores Baksh¹ ; Thomas R.J. Heathman⁵ ; Biren Mistry⁴ ; Nan Zhang⁶
• 关键词：allogeneic ; autologous ; bioreactor ; cell culture ; cell therapy ; scale-out ; scale-up ; stem cell ; tissue engineering
• 刊名：Cytotherapy
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：19
• 期：1
• 页码：9-18
• 全文大小：430 K
• 卷排序：19

文摘

The use of bioreactors in cell therapy applications is on the rise, as clinical trials and commercialization of cell therapy–based products are moving to the forefront of treatment opportunities. This review focuses on the considerations and benefits of using bioreactors for cell therapy manufacturing, with an emphasis on autologous versus allogenic, scalability, tissue engineering, automation and comparability and consistency in the final product. Evaluation and choice of the right bioreactor for any given process and indication is paramount when moving into scalable platforms and processes that can support the cell therapy industry's needs.